72769-114 : Orladeyo 132 mg Oral Pellet
| NDC: | 72769-114 |
| Labeler: | Biocryst Pharmaceuticals, Inc. |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Orladeyo |
| Dosage Form: | Oral Pellet |
| Application #: | NDA219776 |
| Rev. Date: |
NDC Package Codes:
- 72769-114-02: 4 DOSE PACK IN 1 CARTON (72769‑114‑02) / 7 PACKET IN 1 DOSE PACK / 22 PELLET IN 1 PACKET
Active Ingredients:
- Berotralstat Hydrochloride
Dosage Strength:
- 132 mg
Pharmaceutical Classes:
- Cytochrome P450 2D6 Inhibitors [MoA]
- Cytochrome P450 3A4 Inhibitors [MoA]
- Kallikrein Inhibitors [MoA]
- P-Glycoprotein Inhibitors [MoA]
- Plasma Kallikrein Inhibitor [EPC]
Related Products:
Based on records with the same trade name.- 72769-111 Orladeyo 72 mg Oral Pellet by Biocryst Pharmaceuticals, Inc.
- 72769-112 Orladeyo 96 mg Oral Pellet by Biocryst Pharmaceuticals, Inc.
- 72769-113 Orladeyo 108 mg Oral Pellet by Biocryst Pharmaceuticals, Inc.
- 72769-101 Orladeyo 150 mg Oral Capsule by Biocryst Pharmaceuticals Inc.
- 72769-102 Orladeyo 110 mg Oral Capsule by Biocryst Pharmaceuticals Inc.
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 72769-113Next: 72769-181 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.